Patent intelligence · US
US 12257132
Hydrogen-delivering system for a bodily orifice
Hydrogen-delivering system for a bodily orifice
Patent details — US 12257132
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 25, 2025
- Expiration
- Mar 20, 2045
- Applicant
- H2 Universe LLC
- Claims
- 20
- CPC classes
- A61K, A61K33/00
Quick answer
US 12257132 (Hydrogen-delivering system for a bodily orifice) is held by H2 Universe LLC. Status: granted. Granted Mar 25, 2025. Expires Mar 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- H2 Universe LLC
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K33/00
More from H2 Universe LLC
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12257132?
US 12257132 (Hydrogen-delivering system for a bodily orifice) is held by H2 Universe LLC. Status: granted. Granted Mar 25, 2025. Expires Mar 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12257132?
H2 Universe LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 12257132 expire?
Our index shows an expiration date of Mar 20, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.